Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 96

1.

Dipeptidase-1 Is an Adhesion Receptor for Neutrophil Recruitment in Lungs and Liver.

Choudhury SR, Babes L, Rahn JJ, Ahn BY, Goring KR, King JC, Lau A, Petri B, Hao X, Chojnacki AK, Thanabalasuriar A, McAvoy EF, Tabariès S, Schraeder C, Patel KD, Siegel PM, Kopciuk KA, Schriemer DC, Muruve DA, Kelly MM, Yipp BG, Kubes P, Robbins SM, Senger DL.

Cell. 2019 Aug 22;178(5):1205-1221.e17. doi: 10.1016/j.cell.2019.07.017.

PMID:
31442408
2.

Lysophosphatidylcholine is a Major Component of Platelet Microvesicles Promoting Platelet Activation and Reporting Atherosclerotic Plaque Instability.

Diehl P, Nienaber F, Zaldivia MTK, Stamm J, Siegel PM, Mellett NA, Wessinger M, Wang X, McFadyen JD, Bassler N, Puetz G, Htun NM, Braig D, Habersberger J, Helbing T, Eisenhardt SU, Fuller M, Bode C, Meikle PJ, Chen YC, Peter K.

Thromb Haemost. 2019 Aug;119(8):1295-1310. doi: 10.1055/s-0039-1683409. Epub 2019 Aug 2.

3.

Immature Low-Density Neutrophils Exhibit Metabolic Flexibility that Facilitates Breast Cancer Liver Metastasis.

Hsu BE, Tabariès S, Johnson RM, Andrzejewski S, Senecal J, Lehuédé C, Annis MG, Ma EH, Völs S, Ramsay L, Froment R, Monast A, Watson IR, Granot Z, Jones RG, St-Pierre J, Siegel PM.

Cell Rep. 2019 Jun 25;27(13):3902-3915.e6. doi: 10.1016/j.celrep.2019.05.091.

4.

High Throughput Traction Force Microscopy Using PDMS Reveals Dose-Dependent Effects of Transforming Growth Factor-β on the Epithelial-to-Mesenchymal Transition.

Yoshie H, Koushki N, Molter C, Siegel PM, Krishnan R, Ehrlicher AJ.

J Vis Exp. 2019 Jun 1;(148). doi: 10.3791/59364.

PMID:
31205302
5.

CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.

Dankner M, Ouellet V, Communal L, Schmitt E, Perkins D, Annis MG, Barrès V, Caron C, Mes-Masson AM, Saad F, Siegel PM; Canadian Prostate Cancer Biomarker Network.

Am J Pathol. 2019 Jul;189(7):1451-1461. doi: 10.1016/j.ajpath.2019.04.006. Epub 2019 Jun 12.

PMID:
31202437
6.

GPNMB augments Wnt-1 mediated breast tumor initiation and growth by enhancing PI3K/AKT/mTOR pathway signaling and β-catenin activity.

Maric G, Annis MG, MacDonald PA, Russo C, Perkins D, Siwak DR, Mills GB, Siegel PM.

Oncogene. 2019 Jun;38(26):5294-5307. doi: 10.1038/s41388-019-0793-7. Epub 2019 Mar 26.

PMID:
30914799
7.

Afadin cooperates with Claudin-2 to promote breast cancer metastasis.

Tabariès S, McNulty A, Ouellet V, Annis MG, Dessureault M, Vinette M, Hachem Y, Lavoie B, Omeroglu A, Simon HG, Walsh LA, Kimbung S, Hedenfalk I, Siegel PM.

Genes Dev. 2019 Feb 1;33(3-4):180-193. doi: 10.1101/gad.319194.118. Epub 2019 Jan 28.

8.

Exosomal Release of L-Plastin by Breast Cancer Cells Facilitates Metastatic Bone Osteolysis.

Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabariès S, Gettemans J, Siegel PM, Komarova SV.

Transl Oncol. 2019 Mar;12(3):462-474. doi: 10.1016/j.tranon.2018.11.014. Epub 2018 Dec 21.

9.

A Three-Dimensional Dense Collagen Hydrogel to Model Cancer Cell/Osteoblast Interactions.

James-Bhasin M, Siegel PM, Nazhat SN.

J Funct Biomater. 2018 Dec 12;9(4). pii: E72. doi: 10.3390/jfb9040072.

10.

Metabolic Profiles Associated With Metformin Efficacy in Cancer.

Andrzejewski S, Siegel PM, St-Pierre J.

Front Endocrinol (Lausanne). 2018 Aug 21;9:372. doi: 10.3389/fendo.2018.00372. eCollection 2018. Review.

11.

LKB1 deficiency in T cells promotes the development of gastrointestinal polyposis.

Poffenberger MC, Metcalfe-Roach A, Aguilar E, Chen J, Hsu BE, Wong AH, Johnson RM, Flynn B, Samborska B, Ma EH, Gravel SP, Tonelli L, Devorkin L, Kim P, Hall A, Izreig S, Loginicheva E, Beauchemin N, Siegel PM, Artyomov MN, Lum JJ, Zogopoulos G, Blagih J, Jones RG.

Science. 2018 Jul 27;361(6400):406-411. doi: 10.1126/science.aan3975.

PMID:
30049881
12.

Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant Melanomas.

Dankner M, Lajoie M, Moldoveanu D, Nguyen TT, Savage P, Rajkumar S, Huang X, Lvova M, Protopopov A, Vuzman D, Hogg D, Park M, Guiot MC, Petrecca K, Mihalcioiu C, Watson IR, Siegel PM, Rose AAN.

Clin Cancer Res. 2018 Dec 15;24(24):6483-6494. doi: 10.1158/1078-0432.CCR-17-3384. Epub 2018 Jun 14.

PMID:
29903896
13.

DZ-2384 has a superior preclinical profile to taxanes for the treatment of triple-negative breast cancer and is synergistic with anti-CTLA-4 immunotherapy.

Bernier C, Soliman A, Gravel M, Dankner M, Savage P, Petrecca K, Park M, Siegel PM, Shore GC, Roulston A.

Anticancer Drugs. 2018 Sep;29(8):774-785. doi: 10.1097/CAD.0000000000000653.

14.

Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.

Dankner M, Rose AAN, Rajkumar S, Siegel PM, Watson IR.

Oncogene. 2018 Jun;37(24):3183-3199. doi: 10.1038/s41388-018-0171-x. Epub 2018 Mar 15. Review.

PMID:
29540830
15.

Translational control in the tumor microenvironment promotes lung metastasis: Phosphorylation of eIF4E in neutrophils.

Robichaud N, Hsu BE, Istomine R, Alvarez F, Blagih J, Ma EH, Morales SV, Dai DL, Li G, Souleimanova M, Guo Q, Del Rincon SV, Miller WH Jr, Ramón Y Cajal S, Park M, Jones RG, Piccirillo CA, Siegel PM, Sonenberg N.

Proc Natl Acad Sci U S A. 2018 Mar 6;115(10):E2202-E2209. doi: 10.1073/pnas.1717439115. Epub 2018 Feb 20.

16.

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion.

Annis MG, Ouellet V, Rennhack JP, L'Esperance S, Rancourt C, Mes-Masson AM, Andrechek ER, Siegel PM.

Breast Cancer Res. 2018 Jan 30;20(1):9. doi: 10.1186/s13058-018-0936-8.

17.

Emerging roles for LPP in metastatic cancer progression.

Ngan E, Kiepas A, Brown CM, Siegel PM.

J Cell Commun Signal. 2018 Mar;12(1):143-156. doi: 10.1007/s12079-017-0415-5. Epub 2017 Oct 13. Review.

18.

PGC-1α Promotes Breast Cancer Metastasis and Confers Bioenergetic Flexibility against Metabolic Drugs.

Andrzejewski S, Klimcakova E, Johnson RM, Tabariès S, Annis MG, McGuirk S, Northey JJ, Chénard V, Sriram U, Papadopoli DJ, Siegel PM, St-Pierre J.

Cell Metab. 2017 Nov 7;26(5):778-787.e5. doi: 10.1016/j.cmet.2017.09.006. Epub 2017 Oct 5.

19.

Targeting GPNMB with glembatumumab vedotin: Current developments and future opportunities for the treatment of cancer.

Rose AAN, Biondini M, Curiel R, Siegel PM.

Pharmacol Ther. 2017 Nov;179:127-141. doi: 10.1016/j.pharmthera.2017.05.010. Epub 2017 May 22. Review.

PMID:
28546082
20.

LPP is a Src substrate required for invadopodia formation and efficient breast cancer lung metastasis.

Ngan E, Stoletov K, Smith HW, Common J, Muller WJ, Lewis JD, Siegel PM.

Nat Commun. 2017 Apr 24;8:15059. doi: 10.1038/ncomms15059.

21.

Expanding the armamentarium for neutrophil-mediated angiogenesis.

Hsu BE, Siegel PM.

Hepatology. 2017 Jun;65(6):1796-1798. doi: 10.1002/hep.29143. Epub 2017 Apr 28. No abstract available.

PMID:
28267229
22.

The Cdc42/Rac1 regulator CdGAP is a novel E-cadherin transcriptional co-repressor with Zeb2 in breast cancer.

He Y, Northey JJ, Pelletier A, Kos Z, Meunier L, Haibe-Kains B, Mes-Masson AM, Côté JF, Siegel PM, Lamarche-Vane N.

Oncogene. 2017 Jun 15;36(24):3490-3503. doi: 10.1038/onc.2016.492. Epub 2017 Jan 30.

23.

The synthetic diazonamide DZ-2384 has distinct effects on microtubule curvature and dynamics without neurotoxicity.

Wieczorek M, Tcherkezian J, Bernier C, Prota AE, Chaaban S, Rolland Y, Godbout C, Hancock MA, Arezzo JC, Ocal O, Rocha C, Olieric N, Hall A, Ding H, Bramoullé A, Annis MG, Zogopoulos G, Harran PG, Wilkie TM, Brekken RA, Siegel PM, Steinmetz MO, Shore GC, Brouhard GJ, Roulston A.

Sci Transl Med. 2016 Nov 16;8(365):365ra159. Erratum in: Sci Transl Med. 2017 Dec 20;9(421):.

24.

MAPK Pathway Inhibitors Sensitize BRAF-Mutant Melanoma to an Antibody-Drug Conjugate Targeting GPNMB.

Rose AA, Annis MG, Frederick DT, Biondini M, Dong Z, Kwong L, Chin L, Keler T, Hawthorne T, Watson IR, Flaherty KT, Siegel PM.

Clin Cancer Res. 2016 Dec 15;22(24):6088-6098. Epub 2016 Aug 11.

25.

5'-Inositol phosphatase SHIP2 recruits Mena to stabilize invadopodia for cancer cell invasion.

Rajadurai CV, Havrylov S, Coelho PP, Ratcliffe CD, Zaoui K, Huang BH, Monast A, Chughtai N, Sangwan V, Gertler FB, Siegel PM, Park M.

J Cell Biol. 2016 Sep 12;214(6):719-34. doi: 10.1083/jcb.201501003. Epub 2016 Sep 5.

26.

Metabolic Plasticity as a Determinant of Tumor Growth and Metastasis.

Lehuédé C, Dupuy F, Rabinovitch R, Jones RG, Siegel PM.

Cancer Res. 2016 Sep 15;76(18):5201-8. doi: 10.1158/0008-5472.CAN-16-0266. Epub 2016 Sep 1. Review.

27.

The role of claudins in cancer metastasis.

Tabariès S, Siegel PM.

Oncogene. 2017 Mar 2;36(9):1176-1190. doi: 10.1038/onc.2016.289. Epub 2016 Aug 15. Review.

PMID:
27524421
28.

The histone H3K9 demethylase KDM3A promotes anoikis by transcriptionally activating pro-apoptotic genes BNIP3 and BNIP3L.

Pedanou VE, Gobeil S, Tabariès S, Simone TM, Zhu LJ, Siegel PM, Green MR.

Elife. 2016 Jul 29;5. pii: e16844. doi: 10.7554/eLife.16844.

29.

The Tyrosine Kinome Dictates Breast Cancer Heterogeneity and Therapeutic Responsiveness.

Ha JR, Siegel PM, Ursini-Siegel J.

J Cell Biochem. 2016 Sep;117(9):1971-90. doi: 10.1002/jcb.25561. Epub 2016 Apr 14. Review.

PMID:
27392311
30.

Chordin-Like 1 Suppresses Bone Morphogenetic Protein 4-Induced Breast Cancer Cell Migration and Invasion.

Cyr-Depauw C, Northey JJ, Tabariès S, Annis MG, Dong Z, Cory S, Hallett M, Rennhack JP, Andrechek ER, Siegel PM.

Mol Cell Biol. 2016 May 2;36(10):1509-25. doi: 10.1128/MCB.00600-15. Print 2016 May 15.

31.

The influence of the pre-metastatic niche on breast cancer metastasis.

Ursini-Siegel J, Siegel PM.

Cancer Lett. 2016 Sep 28;380(1):281-8. doi: 10.1016/j.canlet.2015.11.009. Epub 2015 Nov 11. Review.

PMID:
26577808
32.

PDK1-Dependent Metabolic Reprogramming Dictates Metastatic Potential in Breast Cancer.

Dupuy F, Tabariès S, Andrzejewski S, Dong Z, Blagih J, Annis MG, Omeroglu A, Gao D, Leung S, Amir E, Clemons M, Aguilar-Mahecha A, Basik M, Vincent EE, St-Pierre J, Jones RG, Siegel PM.

Cell Metab. 2015 Oct 6;22(4):577-89. doi: 10.1016/j.cmet.2015.08.007. Epub 2015 Sep 10.

33.

Granulocytic immune infiltrates are essential for the efficient formation of breast cancer liver metastases.

Tabariès S, Ouellet V, Hsu BE, Annis MG, Rose AA, Meunier L, Carmona E, Tam CE, Mes-Masson AM, Siegel PM.

Breast Cancer Res. 2015 Mar 27;17:45. doi: 10.1186/s13058-015-0558-3.

34.

Lyn modulates Claudin-2 expression and is a therapeutic target for breast cancer liver metastasis.

Tabariès S, Annis MG, Hsu BE, Tam CE, Savage P, Park M, Siegel PM.

Oncotarget. 2015 Apr 20;6(11):9476-87.

35.

Peroxiredoxin 4: a novel secreted mediator of cancer induced osteoclastogenesis.

Rafiei S, Tiedemann K, Tabariès S, Siegel PM, Komarova SV.

Cancer Lett. 2015 Jun 1;361(2):262-70. doi: 10.1016/j.canlet.2015.03.012. Epub 2015 Mar 14.

PMID:
25779674
36.

GPNMB cooperates with neuropilin-1 to promote mammary tumor growth and engages integrin α5β1 for efficient breast cancer metastasis.

Maric G, Annis MG, Dong Z, Rose AA, Ng S, Perkins D, MacDonald PA, Ouellet V, Russo C, Siegel PM.

Oncogene. 2015 Oct;34(43):5494-504. doi: 10.1038/onc.2015.8. Epub 2015 Mar 16.

PMID:
25772243
37.

Serial analysis of 38 proteins during the progression of human breast tumor in mice using an antibody colocalization microarray.

Li H, Bergeron S, Annis MG, Siegel PM, Juncker D.

Mol Cell Proteomics. 2015 Apr;14(4):1024-37. doi: 10.1074/mcp.M114.046516. Epub 2015 Feb 13.

38.

The IGF-Trap: Novel Inhibitor of Carcinoma Growth and Metastasis.

Wang N, Rayes RF, Elahi SM, Lu Y, Hancock MA, Massie B, Rowe GE, Aomari H, Hossain S, Durocher Y, Pinard M, Tabariès S, Siegel PM, Brodt P.

Mol Cancer Ther. 2015 Apr;14(4):982-93. doi: 10.1158/1535-7163.MCT-14-0751. Epub 2015 Feb 11.

39.

Genetic and pharmacologic inhibition of eIF4E reduces breast cancer cell migration, invasion, and metastasis.

Pettersson F, Del Rincon SV, Emond A, Huor B, Ngan E, Ng J, Dobocan MC, Siegel PM, Miller WH Jr.

Cancer Res. 2015 Mar 15;75(6):1102-12. doi: 10.1158/0008-5472.CAN-14-1996. Epub 2015 Jan 21.

40.

Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer.

Bendell J, Saleh M, Rose AA, Siegel PM, Hart L, Sirpal S, Jones S, Green J, Crowley E, Simantov R, Keler T, Davis T, Vahdat L.

J Clin Oncol. 2014 Nov 10;32(32):3619-25. doi: 10.1200/JCO.2013.52.5683. Epub 2014 Sep 29.

PMID:
25267761
41.

Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma.

Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, Nikbakht H, Gerges N, Fiset PO, Bechet D, Faury D, De Jay N, Ramkissoon LA, Corcoran A, Jones DT, Sturm D, Johann P, Tomita T, Goldman S, Nagib M, Bendel A, Goumnerova L, Bowers DC, Leonard JR, Rubin JB, Alden T, Browd S, Geyer JR, Leary S, Jallo G, Cohen K, Gupta N, Prados MD, Carret AS, Ellezam B, Crevier L, Klekner A, Bognar L, Hauser P, Garami M, Myseros J, Dong Z, Siegel PM, Malkin H, Ligon AH, Albrecht S, Pfister SM, Ligon KL, Majewski J, Jabado N, Kieran MW.

Nat Genet. 2014 May;46(5):462-6. doi: 10.1038/ng.2950. Epub 2014 Apr 6.

42.

Arsenic trioxide overcomes rapamycin-induced feedback activation of AKT and ERK signaling to enhance the anti-tumor effects in breast cancer.

Guilbert C, Annis MG, Dong Z, Siegel PM, Miller WH Jr, Mann KK.

PLoS One. 2013 Dec 31;8(12):e85995. doi: 10.1371/journal.pone.0085995. eCollection 2013.

43.

Fusion of TTYH1 with the C19MC microRNA cluster drives expression of a brain-specific DNMT3B isoform in the embryonal brain tumor ETMR.

Kleinman CL, Gerges N, Papillon-Cavanagh S, Sin-Chan P, Pramatarova A, Quang DA, Adoue V, Busche S, Caron M, Djambazian H, Bemmo A, Fontebasso AM, Spence T, Schwartzentruber J, Albrecht S, Hauser P, Garami M, Klekner A, Bognar L, Montes JL, Staffa A, Montpetit A, Berube P, Zakrzewska M, Zakrzewski K, Liberski PP, Dong Z, Siegel PM, Duchaine T, Perotti C, Fleming A, Faury D, Remke M, Gallo M, Dirks P, Taylor MD, Sladek R, Pastinen T, Chan JA, Huang A, Majewski J, Jabado N.

Nat Genet. 2014 Jan;46(1):39-44. doi: 10.1038/ng.2849. Epub 2013 Dec 8.

PMID:
24316981
44.

LKB1 is a central regulator of tumor initiation and pro-growth metabolism in ErbB2-mediated breast cancer.

Dupuy F, Griss T, Blagih J, Bridon G, Avizonis D, Ling C, Dong Z, Siwak DR, Annis MG, Mills GB, Muller WJ, Siegel PM, Jones RG.

Cancer Metab. 2013 Aug 14;1(1):18. doi: 10.1186/2049-3002-1-18.

45.

Glycoprotein non-metastatic b (GPNMB): A metastatic mediator and emerging therapeutic target in cancer.

Maric G, Rose AA, Annis MG, Siegel PM.

Onco Targets Ther. 2013 Jul 9;6:839-52. doi: 10.2147/OTT.S44906. Print 2013.

46.

The ShcA PTB domain functions as a biological sensor of phosphotyrosine signaling during breast cancer progression.

Ahn R, Sabourin V, Ha JR, Cory S, Maric G, Im YK, Hardy WR, Zhao H, Park M, Hallett M, Siegel PM, Pawson T, Ursini-Siegel J.

Cancer Res. 2013 Jul 15;73(14):4521-32. doi: 10.1158/0008-5472.CAN-12-4178. Epub 2013 May 21.

47.

A complex containing LPP and α-actinin mediates TGFβ-induced migration and invasion of ErbB2-expressing breast cancer cells.

Ngan E, Northey JJ, Brown CM, Ursini-Siegel J, Siegel PM.

J Cell Sci. 2013 May 1;126(Pt 9):1981-91. doi: 10.1242/jcs.118315. Epub 2013 Feb 27.

48.

Distinct phosphotyrosine-dependent functions of the ShcA adaptor protein are required for transforming growth factor β (TGFβ)-induced breast cancer cell migration, invasion, and metastasis.

Northey JJ, Dong Z, Ngan E, Kaplan A, Hardy WR, Pawson T, Siegel PM.

J Biol Chem. 2013 Feb 15;288(7):5210-22. doi: 10.1074/jbc.M112.424804. Epub 2012 Dec 31.

49.

AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.

Faubert B, Boily G, Izreig S, Griss T, Samborska B, Dong Z, Dupuy F, Chambers C, Fuerth BJ, Viollet B, Mamer OA, Avizonis D, DeBerardinis RJ, Siegel PM, Jones RG.

Cell Metab. 2013 Jan 8;17(1):113-24. doi: 10.1016/j.cmet.2012.12.001. Epub 2012 Dec 27.

50.

ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone.

Mourskaia AA, Amir E, Dong Z, Tiedemann K, Cory S, Omeroglu A, Bertos N, Ouellet V, Clemons M, Scheffer GL, Park M, Hallett M, Komarova SV, Siegel PM.

Breast Cancer Res. 2012 Nov 22;14(6):R149. doi: 10.1186/bcr3361.

Supplemental Content

Loading ...
Support Center